Salmeterol dry-powder inhalation - GlaxoSmithKline

Drug Profile

Salmeterol dry-powder inhalation - GlaxoSmithKline

Alternative Names: Salmeterol xinafoate dry-powder inhalation - GlaxoSmithKline; Serevent Accuhaler; Serevent Diskhaler; Serevent Diskus; SN 408 dry-powder inhalation - GlaxoSmithKline

Latest Information Update: 28 Jan 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 04 Mar 2004 Serevent® 50 Diskus® has been approved in Japan for Asthma and Chronic obstructive pulmonary disease
  • 06 May 2003 Launched for Asthma in Australia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top